Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The first person to be randomly selected to receive convalescent plasma through RECOVERY has now received a transfusion.

The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial is a national platform trial testing existing treatments that may help people hospitalised with suspected or confirmed COVID-19. 

The inclusion of convalescent plasma in the RECOVERY trial means that many more people will now start to receive convalescent plasma, which is being collected by NHS Blood and Transplant. 

People had already received convalescent plasma through a smaller, more specialised platform trial called REMAP-CAP, which is looking at treatments for pneumonia. The REMAP-CAP trial is not exclusively focused on COVID-19 and only adults in intensive care could receive convalescent plasma. 

RECOVERY is open to patients of any age admitted to hospitals with COVID-19. Selected hospitals are currently able to randomise patients to receive convalescent plasma and this will expand out to all hospitals participating in the RECOVERY trial. 

Read more on the RECOVERY Trial website

Similar stories

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance

Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Peter Horby receives prestigious award for outstanding service to public health

The Faculty of Public Health (FPH) has awarded its prestigious Alwyn Smith Prize to Professor Sir Peter Horby (Nuffield Department of Medicine) for 2020/2021 in recognition of his outstanding service to public health as a global leader in epidemic science.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Researchers set out steps to address mental health effects of the pandemic on young people

Researchers have outlined 14 steps that schools, mental health services and policymakers can take to help children and young people whose mental health has been affected by the COVID-19 pandemic.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.